uniQure (NASDAQ:QURE) Director Rachelle Suzanne Jacques Sells 2,221 Shares of Stock

uniQure (NASDAQ:QURE) Director Rachelle Suzanne Jacques sold 2,221 shares of the firm’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $5.14, for a total value of $11,415.94. Following the completion of the transaction, the director now owns 14,408 shares in the company, valued at approximately $74,057.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

uniQure Price Performance

Shares of uniQure stock opened at $4.69 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 9.27 and a current ratio of 9.39. uniQure has a 52-week low of $4.25 and a 52-week high of $19.63. The stock’s 50-day simple moving average is $4.89 and its 200 day simple moving average is $5.62.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The company had revenue of $8.49 million for the quarter, compared to analysts’ expectations of $2.58 million. On average, equities research analysts forecast that uniQure will post -4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

QURE has been the subject of several recent analyst reports. Mizuho reduced their target price on shares of uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Wednesday, May 8th. The Goldman Sachs Group downgraded shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $63.00 to $8.00 in a research report on Thursday, February 29th. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Friday, March 1st. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.75.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock worth $42,000 after buying an additional 4,315 shares in the last quarter. Nomura Holdings Inc. bought a new stake in shares of uniQure during the 3rd quarter valued at about $67,000. Laurion Capital Management LP purchased a new position in shares of uniQure during the third quarter worth about $73,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of uniQure in the fourth quarter worth approximately $86,000. Finally, Regal Investment Advisors LLC bought a new stake in uniQure during the third quarter valued at approximately $94,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.